acecainide has been researched along with Coronary Disease in 6 studies
Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.
N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antiarrhythmic properties of N-acetylprocainamide (NAPA), an active metabolite of procainamide, were studied in 12 patients with coronary artery disease who presented with cardiac arrest or documented sustained ventricular tachycardia (VT)." | 7.67 | Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease. ( Flowers, D; Keefe, D; Miura, DS; Somberg, JC; Torres, V; Williams, S; Wynn, J, 1985) |
| "Eleven patients with chronic ventricular arrhythmias took part in a study of N-acetylprocainamide (NAPA), the major metabolite of procainamide, in order to characterize further NAPA's clinical pharmacology and antiarrhythmic action." | 5.05 | Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide. ( Jaillon, P; Kates, RE; Peters, F; Winkle, RA, 1981) |
| "Antiarrhythmic properties of N-acetylprocainamide (NAPA), an active metabolite of procainamide, were studied in 12 patients with coronary artery disease who presented with cardiac arrest or documented sustained ventricular tachycardia (VT)." | 3.67 | Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease. ( Flowers, D; Keefe, D; Miura, DS; Somberg, JC; Torres, V; Williams, S; Wynn, J, 1985) |
| "Despite widespread marketing of a sustained release preparation of procainamide hydrochloride (PROCAN-SR, Parke-Davis), published literature demonstrating its efficacy in maintaining uniform serum drug levels over a 6-hour dosing interval is derived from only normal healthy volunteers." | 1.27 | Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation. ( Mirando, T; Zema, MJ, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kates, RE | 2 |
| Jaillon, P | 2 |
| Rubenson, DS | 1 |
| Winkle, RA | 2 |
| Peters, F | 1 |
| Kluger, J | 1 |
| Horner, H | 1 |
| Reidenberg, MM | 1 |
| Zema, MJ | 1 |
| Mirando, T | 1 |
| Reynolds, RD | 1 |
| Kamath, BL | 1 |
| Wynn, J | 1 |
| Miura, DS | 1 |
| Torres, V | 1 |
| Flowers, D | 1 |
| Keefe, D | 1 |
| Williams, S | 1 |
| Somberg, JC | 1 |
1 trial available for acecainide and Coronary Disease
| Article | Year |
|---|---|
Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide.
Topics: Acecainide; Adult; Aged; Arrhythmias, Cardiac; Coronary Disease; Dose-Response Relationship, Drug; E | 1981 |
5 other studies available for acecainide and Coronary Disease
| Article | Year |
|---|---|
Intravenous N-acetylprocainamide disposition kinetics in coronary artery disease.
Topics: Acecainide; Adult; Aged; Coronary Disease; Creatinine; Female; Half-Life; Humans; Infusions, Parente | 1980 |
Effects of procainamide and N-acetylprocainamide on myocardial contractility in ischemic isolated rabbit hearts.
Topics: Acecainide; Animals; Coronary Disease; Disease Models, Animal; Epinephrine; Male; Myocardial Contrac | 1981 |
Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
Topics: Acecainide; Administration, Oral; Adult; Aged; Coronary Disease; Delayed-Action Preparations; Female | 1983 |
N-acetylprocainamide and ischemia-induced ventricular fibrillation in the dog.
Topics: Acecainide; Animals; Blood Pressure; Coronary Disease; Dogs; Electrocardiography; Female; Heart Rate | 1979 |
Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease.
Topics: Acecainide; Aged; Coronary Disease; Electrocardiography; Electrophysiology; Female; Heart Arrest; He | 1985 |